FDA warned Med Shop Inc that its website sells unapproved, misbranded ketamine nasal spray to U.S. consumers.
What happened
FDA reviewed the website www.medshopinc.com on February 27, 2026, rather than doing an inspection. The site offered a product marketed as "Ketamine Nasal Spray" (esketamine) with claims that it treats treatment-resistant depression and chronic pain. FDA said there is no approved application for that product and that its labeling lacks adequate directions for use.
What FDA found
The company sells a ketamine nasal spray without an FDA-approved application, which the law requires for a new drug.
FD&C Act sections 301(d) and 505(a) (21 U.S.C. 331(d), 355(a))Website statements that the spray treats depression and chronic pain show the product is a drug intended for human use.
FD&C Act section 201(g) (21 U.S.C. 321(g)); 21 CFR 201.128The product's labeling does not give adequate directions for use, so it is misbranded.
FD&C Act section 502(f)(1) (21 U.S.C. 352(f)(1))The drug is a prescription drug that a layperson cannot safely use on their own, and it has no exemption from the directions-for-use requirement because it is not approved.
FD&C Act section 503(b)(1) (21 U.S.C. 353(b)(1)); 21 CFR 201.115(a)Offering the misbranded drug for sale to U.S. consumers puts it into interstate commerce illegally.
FD&C Act section 301(a) (21 U.S.C. 331(a))
What FDA wants
FDA tells the company to stop offering unapproved and misbranded drugs to U.S. consumers and to reply in writing within 15 business days with the steps taken to correct and prevent the violations, plus supporting documents, citing reference number MARCS-CMS 725157.
Who should pay attention
- online pharmacies and telehealth sites selling ketamine products
- U.S. clinicians whose patients buy ketamine online
- distributors and compounders shipping ketamine products to U.S. buyers
This is a summary. Read the original letter on fda.gov.